⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ELDN News
Eledon Pharmaceuticals, Inc. Common Stock
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
globenewswire.com
ELDN
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
globenewswire.com
ELDN
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
globenewswire.com
ELDN
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
globenewswire.com
ELDN
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
prnewswire.com
ELDN
NCEL
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
ELDN
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
ELDN
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
ELDN
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
globenewswire.com
ELDN
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
globenewswire.com
ELDN